Business Context and Reporting Period
Company: Greenwave Technology Solutions, Inc. (GWAV)
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2024
Listing: NASDAQ Capital Market
Event: Notice of failure to satisfy the minimum bid price requirement for continued listing.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Listing Status
- Deficiency: The Company's common stock bid price closed below the $1.00 per share minimum requirement for 30 consecutive business days.
- Compliance Period: Nasdaq has granted an initial 180-day compliance period ending March 12, 2025.
- Cure Requirement: To regain compliance, the stock must close at $1.00 or more for 10 consecutive business days before the deadline.
- Immediate Impact: The deficiency letter has no immediate effect on the listing or trading of the Company's common stock.
Outlook, Management Commentary, and Risks
Management Intent: The Company intends to monitor the bid price and consider available options, including a reverse stock split, if necessary to regain compliance.
Future Scenarios:
- If compliance is not met by March 12, 2025, the Company may be eligible for an additional 180-day period, contingent on meeting other listing standards (e.g., market value of publicly held shares).
- If the Company fails to qualify for the second period or cannot cure the deficiency, Nasdaq may notify the Company of delisting.
- The Company may appeal a delisting determination, though there is no assurance of success.
Risks: There is no assurance the Company will meet the bid price requirement, qualify for additional relief, or avoid delisting. Actual results may differ materially from forward-looking statements regarding these outcomes.
Investor Verification Checklist
- Verify the current trading price of GWAV to assess proximity to the $1.00 threshold.
- Monitor the stock's closing prices for the next 10 consecutive business days to track progress toward the cure requirement.
- Review the Company's 10-K filed on April 16, 2024, for detailed risk factors and financial health context not included in this 8-K.
- Watch for future announcements regarding a potential reverse stock split or other capital structure changes.
- Confirm the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first is missed.